

1912 Rt 35 S, Ste 203, Oakhurst, NJ 07755 **P** 732 389 1530 | **F** 732 389 0352 **Courier P** 732 508 9154 genesislaboratory.com

Acc	ession	Info (F	or Ger	nesis La	ab Use)

Primarius Pathology

		Respirator	y Requisition				
Date Specimen Collected: Time Specimen Collected:							
uboratory Use Only Accession Number Date Receive			ed	Time Received			
Practice Name				Practice Contact Information			
Ordering Physicians		Practice ID			Address		
				City, State, Zip			
				Phone			
				Fax			
	(Currently Not Ad	Patient and Insuccepting Medicaid or M	Irance Informa anaged Medicaid P	i <b>tion</b> lans - Contract Pending	)		
First Name				Middle Initial			
Address Line 1							
DOB				Email			
Gender Identity*			-				
				Social Security #			
Home Phone							
Primary Insurance Group #				ance			
Group # Address	_ 1D#		Address	ID#			
City	State Zip			State	Zip		
		Respirator	y Test Panels				
☐ Genesis Respirator	y Pathogen Panel (I	ab: ncluding COVID-19	9) (UTM Swab) (s	See back for details.)	Throat Swab: ☐ Group A Stre		
COVID-19 + Influen COVID-19 ONLY (SA Genesis Expanded **Plea	y Pathogen Panel (II za A & B, and RSV Pa ARS-CoV-2 PCR Ass Respiratory Pathog ase note that an immunocumunodeficiency code is n	ncluding COVID-19 anel (UTM Swab) say) (UTM Swab) ten Panel** (UTM Si	wab) (See back for de must be selected	details.) in order for this test to b	☐ Group A Stro (Liquid Amie	eptococcus es/eSwab)	
COVID-19 + Influen COVID-19 ONLY (SA Genesis Expanded **Plea	za A & B, and RSV Pa ARS-CoV-2 PCR Ass Respiratory Pathog	ncluding COVID-19 anel (UTM Swab) say) (UTM Swab) en Panel** (UTM S deficiency diagnosis con	wab) (See back for de must be selected	details.) in order for this test to b	☐ Group A Stro (Liquid Amie	eptococcus es/eSwab)	
COVID-19 + Influen COVID-19 ONLY (SA Genesis Expanded **Plea	za A & B, and RSV Pa ARS-CoV-2 PCR Ass Respiratory Pathog	ncluding COVID-19 anel (UTM Swab) say) (UTM Swab) en Panel** (UTM S deficiency diagnosis control selected, testing will	wab) (See back for de must be selected l automatically be re	details.) in order for this test to b	☐ Group A Stro (Liquid Amie  De performed.  Respiratory Pathogen	eptococcus es/eSwab)	
COVID-19 + Influen COVID-19 ONLY (SA Genesis Expanded **Plea If an appropriate imi	za A & B, and RSV Pa ARS-CoV-2 PCR Ass Respiratory Pathog ase note that an immuno- munodeficiency code is n  ED BELOW AND MUST BI ry R50.9 Fer U07.1 CO J12.82 Pn J12.89 Ot J20.8 Act stress J22 Unsp	ncluding COVID-19 anel (UTM Swab) say) (UTM Swab) en Panel** (UTM S deficiency diagnosis control selected, testing will	wab) (See back for other demonstrates be selected automatically be recorded or codes	Immunodeficiency IC  D81.89 Other communode icommunode icommunication ic	Group A Stro (Liquid Amie  be performed. espiratory Pathogen  cD-10 Codes bined immunodeficier munodeficiency, uns non variable immunodericie eficiency due to drugs	eptococcus es/eSwab)  Panel".  pricies epecified leficiencies ncy, unspecified	
COVID-19 + Influen COVID-19 ONLY (SA Genesis Expanded  **Plea If an appropriate imm  COVID-19 CODES ARE LISTE J06.9 Acute upper respirato infection, unspecified J11.1 Flu like symptoms R05 Cough R06.02 Shortness of breath R06.03 Acute respiratory dis R06.2 Wheezing	za A & B, and RSV Pa ARS-CoV-2 PCR Ass Respiratory Pathog ase note that an immunor munodeficiency code is n  ED BELOW AND MUST Bi ry R50.9 Fer U07.1 COV J12.82 Pn J12.89 Ot J20.8 Act Stress J22 Unsp A37.90 W	anel (UTM Swab) say) (UTM Swab) say) (UTM Swab) sen Panel** (UTM Size) deficiency diagnosis contot selected, testing will  ICD-1 ECHECKED OFF ever unspecified VID-19 virus identified seumonia due to coronavirula pneumonia ute bronchitis due to other cher viral pneumonia ute bronchitis due to other viral pneumonia	wab) (See back for de must be selected automatically be recorded automatically be respecified organism atory infection	In order for this test to be effexed to the "Genesis R  Immunodeficiency IC  D81.89 Other composite D83.9 Common version D84.821 Immunode D84.821 Immunode D84.89 Other immunode D84.9 Immunodeficiency IC  D84.89 Other immunodeficiency IC  D84.89 Other immunodeficiency IC  D84.89 Other immunodeficiency IC  D84.9 Immunodeficiency IC  El, there must be primary diag	Group A Stra (Liquid Amie  De performed. espiratory Pathogen  D-10 Codes  bined immunodeficier munodeficiency, uns non variable immunode ariable immunodeficie eficiency due to drugs nunodeficiencies iciency, unspecified  be at least phosis code.	eptococcus es/eSwab)  Panel".  ncies specified leficiencies ncy, unspecified s	
COVID-19 + Influen COVID-19 ONLY (SA Genesis Expanded  **Plea If an appropriate imm  COVID-19 CODES ARE LISTE J06.9 Acute upper respirato infection, unspecified J11.1 Flu like symptoms R05 Cough R06.02 Shortness of breath R06.03 Acute respiratory dis R06.2 Wheezing  **For Genesis the imm  This test is medically necessary for impairment, symptom, syndrome	za A & B, and RSV Pa ARS-CoV-2 PCR Ass Respiratory Pathog ase note that an immuno- munodeficiency code is n  ED BELOW AND MUST BI ry R50.9 Fer U07.1 CO' J12.82 Pn J12.89 Ot J20.8 Act stress J22 Unsp A37.90 W  E Expanded Re nunodeficiency or the diagnosis or detection e or disorder. The results will enent decisions. The person lis	anel (UTM Swab) say) (UTM Swab) say) (UTM Swab) sen Panel** (UTM S deficiency diagnosis contot selected, testing will  ICD-1 E CHECKED OFF ver unspecified VID-19 virus identified seumonia due to coronavioner viral pneumonia ute bronchitis due to other cher viral pneumonia ute bronchitis due to other pecified acute lower repiral /hooping cough  of a disease, illness, determine my patient's sted as the ordering	de must be selected automatically be recorded automatically be recorde	In order for this test to be effexed to the "Genesis R  Immunodeficiency IC  D81.89 Other composite D83.9 Common version D84.821 Immunode D84.821 Immunode D84.89 Other immunode D84.9 Immunodeficiency IC  D84.89 Other immunodeficiency IC  D84.89 Other immunodeficiency IC  D84.89 Other immunodeficiency IC  D84.9 Immunodeficiency IC  El, there must be primary diag	Group A Stro (Liquid Amie  De performed.  espiratory Pathogen  D-10 Codes  bined immunodeficier munodeficiency, uns non variable immunode ariable immunodeficie eficiency due to drugs nunodeficiencies iciency, unspecified  be at least phosis code.  The province of the pr	eptococcus es/eSwab)  Panel".  ncies specified leficiencies ncy, unspecified s	

## Genesis Respiratory Pathogen Panel

#### Viruses

Adenovirus
COVID-19 (SARS-CoV-2)
Human Metapneumovirus
Influenza A virus/Influenza B virus Pan

Respiratory syncytial virus

Bacteria

Legionella pneumophila

Bordetella pan (bronchiseptica, parapertussis, pertussis) Bordetella pertussis Chlamydia pneumoniae Mycoplasma pneumoniae

COVID-19 + Influenza A & B, and RSV Panel	COVID-19 ONLY	Group A Streptococcus
COVID-19 (SARS-CoV-2) Influenza A	COVID-19 (SARS-CoV-2)	Streptococcus pyogenes
Influenza B		
Respiratory Syncytial Virus (RSV)		

# Genesis Expanded Respiratory Pathogen Panel

### **Viruses**

Adenovirus Influenza A virus A/H3 Coronavirus 229E Influenza A virus A/H1-2009 Influenza B virus Coronavirus HKU1 Coronavirus NL63 Parainfluenza virus 1 Parainfluenza virus 2 Coronavirus OC43 COVID-19 (SARS-CoV-2) Parainfluenza virus 3 Parainfluenza virus 4 Human Metapneumovirus Human Rhinovirus/Enterovirus Respiratory syncytial virus

#### **Bacteria**

Bordetella pan (bronchiseptica, parapertussis, pertussis) Bordetella pertussis Chlamydia pneumoniae Mycoplasma pneumoniae

Influenza A virus
Influenza A virus A/H1

\*\*For Genesis Expanded Respiratory Pathogen Panel, there must be <u>at least one</u> of the immunodeficiency codes in addition to the primary diagnosis code.

### COVID-19

#### Information about COVID-19 (SARS-CoV-2 PCR Assay)

PLEASE NOTE: Testing was performed using the TaqPath COVID-19 Combo Kit and/or Panther Fusion® SARS-CoV-2 Assay Kit by real-time (RT) PCR. Positive results do not rule out co-infection with organisms not included in the TaqPath COVID-19 Combo Kit and/or Panther Fusion® SARS-CoV-2 Assay Kit by real-time (RT) PCR. The agent detected may not be the definite cause of this disease. This assay is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA). This test is only authorized for the duration of time of the declaration and for the detection of SARSCoV-2 RNA virus and/or diagnosis of COVID-19 infection under section 564 (b)(1) of the act, 21 U.S.C.360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.

A Positive result indicates the presence of SARS-CoV-2 RNA but does not exclude bacterial infection and/or coinfection with other viruses. The agent detected may not be the definitive cause of disease. This result should be combined with clinical observation, patient history, and epidemiological information for patient management decisions.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment and other patient management decisions. Negative results must be used in conjunction with clinical observation, patient history, and epidemiological information for patient management decisions.